Boston, 27 march 2026
The Fifth Transatlantic Exchange in Oncology,
A Collaborative Approach to Delivering Excellence
With the exclusive participation of Dana-Farber Cancer Institute and Gustave Roussy (France)
the Fifth Transatlantic Exchange in Oncology, is focusing this year on Transatlantic Innovations in Cancer Drug Research.
This key event continues the long-standing and highly successful collaborative partnership between Dana-Farber Cancer Institute (Boston) and Gustave Roussy (France), with the support of L'Institut Servier. This event will take place on Friday, March 27, 2026, from 9:00 AM - 5:00 PM ET at Dana-Farber Cancer Institute in Boston, MA.
Discussions will include epigenetic therapies, microbiome-driven immunity and cellular pathway reprogramming. Together, attendees will discover breakthrough technologies and transformative approaches that promise to redefine cancer care worldwide from global pioneers.
Professor Toni Choueiri, Medical Director of International Strategic Initiatives and Director of the Lank Center for Genitourinary Oncology at Dana-Farber and Harvard Medical School, emphasized the program's enduring mission: “Our meetings and previous programs connect the best minds in oncology across continents, to share and discuss emerging trends and the latest innovations amongst colleagues, from translational research, to clinical care with the aim to help facilitate our shared aim, to cure cancer”.
Professor Alexandra Leary, Lead for International Academic Partnerships and Deputy Director of the Department of Medical Oncology, Gustave Roussy (France): “Cancer knows no borders, and neither should innovation. The Transatlantic Exchange embodies our shared belief that by bringing together bold ideas, diverse expertise, and a common purpose, we can redefine what is possible in cancer care. This transatlantic partnership is not only advancing science, it is building a future of hope for patients across the world.”
Patrick Therasse, Managing Director, L'Institut Servier, reiterates this event’s significance: “The Fifth Transatlantic Exchange exemplifies our shared commitment to advancing cancer research through global collaboration. By bringing together leading experts from both sides of the Atlantic, we foster innovation and accelerate progress toward better outcomes for patients everywhere.”
Medscape Medical Affairs is proud to support the organisation of this meeting for the fifth year in a row.
Previous meetings in the series have focused on cutting-edge topics, including Immuno-Oncology, AI/Data Science in Oncology, Liquid Biopsy, and Radioligands.
The Fifth Transatlantic Exchange is free to attend and open to healthcare professionals with an interest in oncology. Registration is now open for both in-person and online registration https://events.medscapelive.org/website/91657/
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.
Dana-Farber is the only hospital nationwide with a top 3 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,200 clinical trials.
About L’Institut Servier
L’Institut Servier is a non-profit organization created in 1999 to advance medical progress. It supports innovative research in oncology, neurodegenerative and cardiovascular diseases. Guided by an independent scientific committee, the Institute promotes excellence, nurtures emerging talent, and fosters the exchange of scientific knowledge through its awards, support programs and international events.
About Gustave Roussy
Ranked as the #1 European cancer center and #6 World’s Best Specialized Hospitals – Oncology by Newsweek magazine in 2025, Gustave Roussy is a center with comprehensive expertise, and is devoted entirely to the care of patients with cancer.
Gustave Roussy is a founding member of the Paris Saclay Cancer Cluster (PSCC), and a source of diagnostic and therapeutic advances. It caters to almost 54,000 patients per year, including 2,760children and adolescents, and its approach is one that integrates research, patient care, and teaching.
While Gustave Roussy is specialized in the treatment of rare cancers and complex tumors, it treats all cancers in patients of any age. Care is personalized, and combines the most advanced medical methods with an appreciation of the patient’s human requirements. In addition to the quality of treatment offered, the physical, psychological, and social aspects of the patient’s life are respected. With 4,000 professionals across two campuses (the Gustave Roussy Institute in Villejuif and the Chevilly-Larue Hospital in Chevilly-Larue), Gustave Roussy brings together the skills that are essential for the highest quality research in oncology; 40,5% of patients treated across the two sites are included in clinical studies.
About Medscape Medical Affairs
Medscape Medical Affairs is redefining how medical affairs teams engage, educate, and measure impact in a rapidly evolving healthcare landscape. We go beyond traditional content delivery, leveraging Medscape’s position as the world’s largest professional medical information platform, trusted by 6.5 million physicians and 13 million healthcare professionals (HCPs), to drive meaningful change in clinical behavior.
Our approach is built on an integrated, data-driven strategy to deliver the right message to the right HCP at the right time. By integrating our four key pillars, Medscape Medical Affairs provides high-quality, results-driven campaigns that align with pharmaceutical objectives, measure success at every stage, and ultimately drive improvements in clinical practice.